# Chongqing Taihao Pharmaceutical Co., Ltd. – FDA Inspection, May 10, 2018

Source: https://www.keypedia.com/records/fda_inspections/chongqing-taihao-pharmaceutical-co-ltd/a234efbe-d0a6-478a-ba4a-8305abb3b913
Source feed: FDA_Inspections

> FDA inspection 1060256 of Chongqing Taihao Pharmaceutical Co., Ltd., May 10, 2018. Classification: No Action Indicated (NAI). 2 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1060256
- Company Name: Chongqing Taihao Pharmaceutical Co., Ltd.
- Inspection Date: 2018-05-10
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- [FDA Inspection 920921 - 2015-03-13](https://www.keypedia.com/records/fda_inspections/chongqing-taihao-pharmaceutical-co-ltd/d78e8144-d4a9-4a27-8a62-cc899c8a4ddb)
- FDA Inspection 784879 - 2012-05-23

## Related Officers

- [FDA Associated Person](https://www.keypedia.com/people/brandon-c-heitmeier/09e1b64b-01de-4f8b-819a-1179d8b4c0c1)

Company: https://www.keypedia.com/companies/chongqing-taihao-pharmaceutical-co-ltd/827eb932-e32e-4fde-8c00-4b54c2302911

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c